This product is no longer promoted on Made-in-China.com. If you find any infringement or sensitive information of it, please contact us for handling. Thank you.
  • Dobutamine Hydrochloride CAS 34368-04-2 for Injection Gard
  • Dobutamine Hydrochloride CAS 34368-04-2 for Injection Gard
  • Dobutamine Hydrochloride CAS 34368-04-2 for Injection Gard

Dobutamine Hydrochloride CAS 34368-04-2 for Injection Gard

Diamond Member Since 2020

Suppliers with verified business licenses

Trading Company

Basic Info.

Model NO.
powder for injection
Use
Injection
Dosage
20mg/Vial
Transport Package
Box
Specification
20mg
Trademark
sunbiolab
Origin
China
Production Capacity
50000 Vial /Month

Product Description

Product Name dobutamine hydrochloride powder for injection
Contents dobutamine hydrochloride 20mg
Package 1vial and 1 Solvent
Store Store below 25oC.Protect from light .
Shelf Lift 36 month
KEEP OUT OF REACH OF CHILDREN.

WE CAN PROVIDE MAKE FORMEULATION (OEM)
 
 
Tren 100
Trenbolone Acetate
Trenbolone Enanthate
50mg/ml
50mg/ml,10ml/vial

Dobutamine - Clinical Pharmacology

Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the β receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. In animal studies, Dobutamine hydrochloride produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol.

In patients with depressed cardiac function, both Dobutamine hydrochloride and isoproterenol increase the cardiac output to a similar degree. In the case of Dobutamine hydrochloride, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines.

Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation.

Systemic vascular resistance is usually decreased with administration of Dobutamine hydrochloride. Occasionally, minimum vasoconstriction has been observed.

Most clinical experience with Dobutamine hydrochloride is short-term − not more than several hours in duration. In the limited number of patients who were studied for 24, 48, and 72 hours, a persistent increase in cardiac output occurred in some, whereas output returned toward baseline values in others.

The onset of action of Dobutamine is within 1 to 2 minutes; however, as much as 10 minutes may be required to obtain the peak effect of a particular infusion rate.

The plasma half-life of Dobutamine hydrochloride in humans is 2 minutes. The principal routes of metabolism are methylation of the catechol and conjugation. In human urine, the major excretion products are the conjugates of Dobutamine and 3-O-methyl Dobutamine. The 3-O-methyl derivative of Dobutamine is inactive.

Alteration of synaptic concentrations of catecholamines with either reserpine or tricyclic antidepressants does not alter the actions of Dobutamine in animals, which indicates that the actions of Dobutamine hydrochloride are not dependent on presynaptic mechanisms.

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now